Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
<p><strong>Background:</strong> The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
F1000Research
2020
|
| _version_ | 1826304034436284416 |
|---|---|
| author | Adams, ER Ainsworth, M Anand, R Andersson, MI Auckland, K Baillie, JK Barnes, E Beer, S Bell, JI Berry, T Bibi, S Carroll, M Chinnakannan, SK Clutterbuck, E Cornall, RJ Crook, DW de Silva, T Dejnirattisai, W Dingle, KE Dold, C Espinosa, A Eyre, DW Farmer, H Fernandez Mendoza, M Georgiou, D Hoosdally, SJ Hunter, A Jefferey, K Kelly, D Klenerman, P Knight, J Knowles, C Kwok, AJ Leuschner, U Levin, R Liu, C López-Camacho, C Martinez, J Matthews, PC McGivern, H Mentzer, AJ Milton, J Mongkolsapaya, J Moore, SC Oliveira, MS Pereira, F Perez, E Peto, T Walker, AS Et al. |
| author_facet | Adams, ER Ainsworth, M Anand, R Andersson, MI Auckland, K Baillie, JK Barnes, E Beer, S Bell, JI Berry, T Bibi, S Carroll, M Chinnakannan, SK Clutterbuck, E Cornall, RJ Crook, DW de Silva, T Dejnirattisai, W Dingle, KE Dold, C Espinosa, A Eyre, DW Farmer, H Fernandez Mendoza, M Georgiou, D Hoosdally, SJ Hunter, A Jefferey, K Kelly, D Klenerman, P Knight, J Knowles, C Kwok, AJ Leuschner, U Levin, R Liu, C López-Camacho, C Martinez, J Matthews, PC McGivern, H Mentzer, AJ Milton, J Mongkolsapaya, J Moore, SC Oliveira, MS Pereira, F Perez, E Peto, T Walker, AS Et al. |
| author_sort | Adams, ER |
| collection | OXFORD |
| description | <p><strong>Background:</strong> The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices.</p>
<p><strong>Methods:</strong> We tested plasma for COVID (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices. We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142).</p>
<p><strong>Results:</strong> ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.</p>
<p><strong>Conclusions:</strong> Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. However, ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.</p> |
| first_indexed | 2024-03-07T06:11:43Z |
| format | Journal article |
| id | oxford-uuid:efbc1f27-a21a-46ca-aada-55f1dbec1de9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:11:43Z |
| publishDate | 2020 |
| publisher | F1000Research |
| record_format | dspace |
| spelling | oxford-uuid:efbc1f27-a21a-46ca-aada-55f1dbec1de92022-03-27T11:42:38ZAntibody testing for COVID-19: A report from the National COVID Scientific Advisory PanelJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:efbc1f27-a21a-46ca-aada-55f1dbec1de9EnglishSymplectic ElementsF1000Research2020Adams, ERAinsworth, MAnand, RAndersson, MIAuckland, KBaillie, JKBarnes, EBeer, SBell, JIBerry, TBibi, SCarroll, MChinnakannan, SKClutterbuck, ECornall, RJCrook, DWde Silva, TDejnirattisai, WDingle, KEDold, CEspinosa, AEyre, DWFarmer, HFernandez Mendoza, MGeorgiou, DHoosdally, SJHunter, AJefferey, KKelly, DKlenerman, PKnight, JKnowles, CKwok, AJLeuschner, ULevin, RLiu, CLópez-Camacho, CMartinez, JMatthews, PCMcGivern, HMentzer, AJMilton, JMongkolsapaya, JMoore, SCOliveira, MSPereira, FPerez, EPeto, TWalker, ASEt al.<p><strong>Background:</strong> The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices.</p> <p><strong>Methods:</strong> We tested plasma for COVID (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices. We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142).</p> <p><strong>Results:</strong> ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.</p> <p><strong>Conclusions:</strong> Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. However, ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.</p> |
| spellingShingle | Adams, ER Ainsworth, M Anand, R Andersson, MI Auckland, K Baillie, JK Barnes, E Beer, S Bell, JI Berry, T Bibi, S Carroll, M Chinnakannan, SK Clutterbuck, E Cornall, RJ Crook, DW de Silva, T Dejnirattisai, W Dingle, KE Dold, C Espinosa, A Eyre, DW Farmer, H Fernandez Mendoza, M Georgiou, D Hoosdally, SJ Hunter, A Jefferey, K Kelly, D Klenerman, P Knight, J Knowles, C Kwok, AJ Leuschner, U Levin, R Liu, C López-Camacho, C Martinez, J Matthews, PC McGivern, H Mentzer, AJ Milton, J Mongkolsapaya, J Moore, SC Oliveira, MS Pereira, F Perez, E Peto, T Walker, AS Et al. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel |
| title | Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel |
| title_full | Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel |
| title_fullStr | Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel |
| title_full_unstemmed | Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel |
| title_short | Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel |
| title_sort | antibody testing for covid 19 a report from the national covid scientific advisory panel |
| work_keys_str_mv | AT adamser antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT ainsworthm antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT anandr antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT anderssonmi antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT aucklandk antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT bailliejk antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT barnese antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT beers antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT bellji antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT berryt antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT bibis antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT carrollm antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT chinnakannansk antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT clutterbucke antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT cornallrj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT crookdw antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT desilvat antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT dejnirattisaiw antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT dingleke antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT doldc antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT espinosaa antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT eyredw antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT farmerh antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT fernandezmendozam antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT georgioud antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT hoosdallysj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT huntera antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT jeffereyk antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT kellyd antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT klenermanp antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT knightj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT knowlesc antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT kwokaj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT leuschneru antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT levinr antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT liuc antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT lopezcamachoc antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT martinezj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT matthewspc antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT mcgivernh antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT mentzeraj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT miltonj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT mongkolsapayaj antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT mooresc antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT oliveirams antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT pereiraf antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT pereze antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT petot antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT walkeras antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel AT etal antibodytestingforcovid19areportfromthenationalcovidscientificadvisorypanel |